Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.

Abstract: Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector.

Abstract: A composition comprising particles formed of poly(diaminosulfide) and one or more leptospiral antigens, and methods of making and using the composition, are provided.

Abstract: Methods of treating or preventing stress, anxiety, or postoperative cognitive dysfunction. Also provided are methods of improving resilience in a subject by administering a therapeutically effective amount of isolated mycobacterium.

Abstract: Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.

Abstract: Ferritin proteins comprising a mutation replacing a surface-exposed amino acid with a cysteine, an N- or C-terminal linker comprising a cysteine, and/or one or more immune-stimulatory moieties linked to the ferritin protein via a surface-exposed amino acid are disclosed. The ferritin proteins can further comprise a non-ferritin polypeptide and be antigenic, e.g., for use in eliciting antibodies against the non-ferritin polypeptide.

Abstract: Provided is a method to generate a recombinant virus that can stably express target proteins. The recombinant virus of the present invention is useful for producing an immunogenic composition or vaccine.

Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.

Abstract: The present invention provides, among other things, modified recombinant HA polypeptides with broadened immunogenic profile that extends coverage to antigenically distinct influenza strains and methods of making and using the same.

Abstract: An immunogenic composition, a SARS-CoV-2 vaccine and a vector are introduced. The immunogenic composition has a recombinant protein having a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and any polypeptide encoded by a polynucleotide which is at least 80% homologous with SEQ ID NO: 1-4, wherein the recombinant protein contains an IgG1 Fc protein fragment having a length of at least 6 amino acids; or a nucleic acid molecule encoding the recombinant protein. The SARS-CoV-2 vaccine has the above recombinant protein or the nucleic acid molecule encoding the above recombinant protein. The vector has the nucleic acid molecule encoding the above recombinant protein.

Abstract: The invention relates to the use of melanin, complexed with an antigen, as a immunostimulatory composition.

Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one antigen, wherein the adjuvant is a cationic lipid. The disclosure also provides methods of treating a disease in a mammal, methods of preventing a disease in a mammal, and methods of effecting antigen cross presentation to induce a humoral immune response and a cellular immune response in a mammal utilizing the vaccine compositions. Cross presentation of various antigens can be achieved by formulating the specific antigens with cationic lipids possessing adjuvant properties.

Abstract: The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.

Abstract: The present invention provides methods for reducing or eliminating a patient's need for lipoprotein apheresis therapy. The methods of the present invention comprise administering to a patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody. The methods of the present invention are useful for treating patients with hyperlipidemia and related conditions who are currently being treated with a therapeutic regimen comprising lipoprotein apheresis (e.g., LDL apheresis or Lp(a) apheresis).

Abstract: Systems, methods, and devices for administering, improving administration, or enabling the selective delivery of an agent to a target portion of a tissue are disclosed. An MRI device, at least high strength (e.g., at least 3 T), more preferably ultra high strength (e.g., at least 10 T) is directed at and applied to a target portion of a tissue, preferably brain tissue. A magnetic field is applied to the target portion of the tissue, selectively increasing local temperature and not impacting core temperature. The agent, preferably exosome carrying a therapeutic, is administered to the patient, and the agent is selectively delivered to the target portion of the tissue. Magnetic fields are optionally applied to the target portion before, during, or after administering the agent, or combinations thereof.

Abstract: The present invention provides a bilirubin nanoparticle formed by the self-assembly of bilirubin and a composite comprising a hydrophilic polymer, a use thereof, and a preparation method therefor. The bilirubin nanoparticle according to the present invention can release a drug enclosed therein to the outside by being collapsed by light or active oxygen stimulation. The bilirubin nanoparticle according to the present invention exhibits antioxidant, antiangiogenic, anticancer, and anti-inflammatory activities.

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TREM2. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder mediated by TREM2.

Abstract: The subject invention pertains to compositions and methods for making and use of metal-based coated nanoparticles. The metal-based, PEG-coated nanoparticles of the invention comprise folic acid molecules on their surface exercise dual functionality by specifically targeting renal tubule cells and treating renal fibrosis.

Abstract: A carrier-free nanoparticle based on the self-assembly of curcumin-erlotinib conjugate (EPC) that exhibits stronger cell killing, better anti-migration effects, and anti-invasion effects for pancreatic cancer cells than the combination of free curcumin and erlotinib.

Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.

Abstract: The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals.

Abstract: Described herein are cyclophanes, compositions, and methods for live cell imaging. The cyclophanes comprise an ordered, cyclic arrangement of a chromophore, a first linker unit, a molecular strut, and a second linker unit. The compositions are capable of being taking up by cells and resist photobleaching under live-cell imaging conditions.

Abstract: Provided are photoacoustic imaging contrast agents that include at least one radiation-absorbing component comprising a copper-complexed and/or manganese-complexed chlorin and/or bacteriochlorin and/or a derivative thereof, or a combination thereof. Also provided are methods for using the disclosed photoacoustic imaging contrast agents either singly or in combination for generating an image of a volume, optionally a subject or a body part, cell, tissue, or organ thereof. Further provided are compositions and methods for multiplex photoacoustic imaging of a volume, optionally a subject or a body part, cell, tissue, or organ thereof using photoacoustic imaging contrast agents that include a plurality of the presently disclosed copper-complexed and/or manganese-complexed chlorins and/or bacteriochlorins and/or derivatives thereof simultaneously.

Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

Abstract: A radioisotope elution system is provided, that has at least a component comprised in a cabinet and accessible via a door equipped with an authentication system to ensure safety. The system may also have a user interface equipped with an authentication system. It is also provided a radioisotope elution system that has a dose calibrator equipped with a lifting mechanism for lifting and/or lowering the vial to be tested in the dose calibrator. Advantageously, the lifting mechanism may be controlled for preventing the vial from being lifted during a quality control test on a sample of eluate in the vial. This feature prevents a user from tampering and/or interfering with the vial while a quality control testing is in progress. In another feature, there is provided a radioisotope elution system with a scanning system for entering information about the radioisotope generator and/or the patient in the system. Systems ensuring that the eluant reservoir contains a saline solution are proposed.

Abstract: Some embodiments relate to imageable radioisotopic microspheres. In some embodiments, the imageable microspheres are radiolabeled with imageable radioisotopes. In some embodiments, the imageable radioisotope is directly coupled to a surface of a substrate of the microsphere. In some embodiments, the imageable microspheres can be used as surrogate particles to predict the distribution of therapeutic microspheres comprising radiotherapeutic isotopes.

Abstract: The present invention relates to a dental composition comprising a radically polymerizable compound, a redox initiator system comprising one or more clathrate compounds comprising a host molecule and one or more guest molecules, wherein the host molecule is selected from cyclodextrines, crown ethers, cucurbituriles and calixarenes and the one or more guest molecules are reducing agents, and an oxidizing agent. Furthermore, the present invention relates to a use of the redox initiator system in a dental composition.

Abstract: An orthodontic article is described comprising the reaction product of a free-radically polymerizable resin; a first free-radical photoinitiator having sufficient absorbance at a first wavelength range; and a second free-radical initiator selected from a second photoinitiator having sufficient absorbance at a second wavelength range, wherein the second wavelength range is different than the first wavelength range, or a thermal free-radical initiator. In some embodiments, the first free-radical photoinitiator exhibits a maximum absorbance at a wavelength of the range of 370-380 nm or 320-330 nm and/or comprises photoinitiator groups selected from acyl phosphine oxide or alkyl amine acetophenone. Also described are photopolymerizable compositions and methods.

Abstract: A wearable article, a moisturizing composition and a method for preparing a wearable article have been disclosed. The wearable article includes at least a layer of a flexible material, wherein the flexible material is an elastomeric material and an inner surface of the layer of flexible material is a coated with a coating formulation comprising 1% to 7% by weight of a moisturizing composition and 93% to 99% by weight of solvent. The moisturizing composition includes 10 to 30% by weight of at least one humectant and 1.0 to 5.4% by weight of at least one antioxidant. Thereby, the present invention reduces transepidermal water loss (TEWL) and promotes skin barrier recovery.

Abstract: An oral care article in form of a strip for use in the oral cavity. The oral care article comprises a solid hydrophobic delivery carrier comprising solid hydrophilic particles comprising a bleaching agent, wherein the solid hydrophilic particles are embedded in the carrier. The concentration of the bleaching agent at a first surface of the solid delivery carrier is greater than the concentration of the bleaching agent at a second surface of the solid delivery carrier and the overall concentration of the bleaching agent is from about 0.1% to about 15% by weight of the article.

Abstract: Described herein, a transparent soap bar for cleaning the skin including a soap surfactant, a synthetic surfactant, a fragrance component, an amine component, an antioxidant salt, wherein the transparent soap bar has a percent transmittance (% T) value of greater than 40% as measured using the method of Measurement of % Transmittance.

Abstract: The invention relates to lamellar liquid composition comprising acyl isethionate, methyl acyl taurate, amphoteric and/or zwitterionic surfactant. Unexpectedly, applicants have found that, when ratio of isethionate to taurate is kept at about to 1:1, enhanced lather is achieved. Other criticalities include ratio of amphoteric and/or zwitterionic to anionic surfactant, total amount of surfactant, and pH.

Abstract: A clear personal cleansing composition having an anionic surfactant, a cationic deposition polymer, an aqueous carrier and a level of inorganic salt of from about 0 to about 1 wt %. The composition is substantially free of sulfates and has a % T of greater than about 80%. The composition can further comprise amphoteric surfactants. The composition remains phase stable and minimizes coacervate formulation until after dilution with water.

Abstract: Semiconductor colloids grafted covalently with an antioxidant, the colloids being semiconductor colloids constituted by at least one element chosen from the group comprising C, Si, Ge, Sn, S, Se, Te, B, N, P, As, Al, Sb, Ga, In, Cd, Zn, O, Cu, Cl, Pb, Tl, Bi, Ti, U, Ba, Sr, Li, Nb, La, I, Mo, Mn, Ca, Fe, Ni, Eu, Cr, Br, Ag, Pt, Hg, and combinations thereof.

Abstract: Provided is a composition for preventing hair loss or promoting hair development, comprising, as an active ingredient, phellandrene or a pharmaceutically acceptable salt thereof. More specifically, provided is a pharmaceutical composition, a quasi-drug composition, a cosmetic composition, or a health functional food composition, for preventing hair loss, treating hair loss, promoting hair development, or promoting hair growth, the composition comprising phellandrene or a salt thereof as an active ingredient.

Abstract: A cosmetic composition for makeup removal and its use for removing facial make-up are disclosed. The composition includes a water-soluble surfactant and an oil-soluble surfactant and. The composition, more specifically, includes, as an active ingredient, a mixture of a water-soluble surfactant having a hydrophile-lipophile balance (HLB) value of 13 or more and an oil-soluble surfactant having an HLB value of 12 or less. The composition can excellently remove makeup residues resulting from using a makeup product, can excellently improve the transparency of the composition, and is excellent in feeling of use on the skin.

Abstract: Described herein are zinc-amino acid-lauryl sulfate complexes and oral care compositions comprising the same; and methods of making and using the same are also described.

Abstract: Leave-on oral care compositions comprising a hyaluronic acid or a salt thereof having good spreadability and improved retention period are provided for promoting Gum Health of a user.

Abstract: The instant disclosure generally relates to a coloring composition for coloring mammalian or synthetic keratin fibers or keratinous surfaces. The composition comprising a medium, optionally pigment microparticles and at least one dye, in particular at least one peri-arylene dye dissolved in the medium. Methods of using such compositions are also described herein.

Abstract: Compositions, methods, and kits for cleansing, moisturizing, soothing, cooling, such as those, for example, that may be used to cleanse, moisturize, soothe, and cool the body or portions thereof.

Abstract: A bruise removal cream includes a combination of coconut oil, salt, and mullein garlic. The cream is mixed in accordance with predetermined ratios by weight and is selectively heated to ensure the dissolving of the salt. A method of application of the bruise removal cream to the surface of the base skin is provided. Application includes rubbing the cream onto the surface of the bruise. The cream should be applied upwards of four times daily.

Abstract: An implantable device contains a drug or biosensing compound, protected from the external environment within a human body by several barriers which are broken upon activation of the device through electrothermal, chemical, and mechanical processes. The device allows accurate and repeated dosing within a human body, thus reducing the number of implantation procedures required. This device extends the lifetime of a biosensor, reducing the number of implantation procedures required.

Abstract: Provided herein are oral liquid formulations of hydrocortisone. Also provided herein are methods of making and using hydrocortisone oral liquid compositions for the treatment of certain diseases including endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, and others.

Abstract: An herbal composition includes a plurality of herbal components designed to work harmoniously together to alleviate pain and reduce inflammation of the oral mucosa. Such pain and inflammation may be associated with, for example, recurrent aphthous stomatitis. The formulation can include ginger, cayenne, cloves, cinnamon, turmeric, and annatto. The herbal composition may be formulated as a candy or gum, for example, to provide effective delivery to the oral mucosa.

Abstract: Nanoparticles including tacrolimus, and a method for providing nanoparticles including tacrolimus as well as to nanoparticles including tacrolimus that are obtainable by said method. Also relates to the nanoparticles including tacrolimus for use as a medicament. Further relates to a mucoadhesive buccal film containing the nanoparticles including tacrolimus and the mucoadhesive buccal film for use as a medicament, especially in pediatric patients.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and an antagonist of an opioid receptor, an inverse agonist of an opioid receptor, or a prodrug thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of the effects of acute opioid overdose, or the use of such a film in reducing the risk of opioid abuse.

Abstract: A Cannabis juice purée is packaged using high pressure processing (HPP). First, a Cannabis juice purée is formed by collecting raw Cannabis material and blending the raw Cannabis material together with a thickening agent and a sweetening agent. Next, the Cannabis juice purée is deposited into a container and the container is processed using HPP. In HPP, the Cannabis juice purée is loaded into a high-pressure chamber filled with pressure transmitting fluid, such as water. The pressure is applied to the Cannabis juice purée. A lid is used to seal the opening of the container. HPP allows the mixture to be pasteurized without applying heat. HPP extends the shelf life of the Cannabis juice purée to several weeks to months without applying heat that could undesirably decarboxylating the cannabinoids present in the Cannabis juice purée. Shelf life is preserved while providing a liquid beverage form of Cannabis juice purée.

Abstract: A liposome vesicle comprising a membrane consisting of 1,3-diheptadecanamidopropan-2-yl(2-(trimethylammonio)ethyl)phosphate surrounding a volume comprising a pharmaceutical drug or contrast agent. The vesicle is mechanosensitive at body temperature and at physiologically or pathophysiologically relevant shear stress.

Abstract: Certain embodiments of the invention provide methods of ameliorating an infusion reaction in a mammal in need thereof.